Kisspeptin (KP-10) vs MOTS-C
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Kisspeptin (KP-10) and MOTS-C (also searched as MOTS-C vs Kisspeptin (KP-10)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Kisspeptin (KP-10) centers on neuro, while MOTS-C leans toward metabolic. On indexed research, MOTS-C is ahead (Kisspeptin (KP-10): 25 studies, Human clinical; MOTS-C: 29, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Kisspeptin (KP-10) is strongest for neuro; MOTS-C for metabolic.
- •Evidence: Kisspeptin (KP-10) Human clinical (25 studies) vs MOTS-C Human evidence (29).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
KISS1R Activation | Fertility Regulation
Metabolic regulation | Male fertility
Kisspeptin (KP-10) vs MOTS-C: side-by-side
| Metric | Kisspeptin (KP-10) | MOTS-C |
|---|---|---|
| Class | Healing | Metabolic |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 25 | 29 |
| Research level | Well Studied | Emerging |
| Strongest effect | Neuro & mood | Metabolic & appetite |
| Healing & recovery | 0.0 | 3.0▲ |
| Muscle & body comp | 0.0 | 2.0▲ |
| Metabolic & appetite | 0.0 | 4.0▲ |
| Neuro & mood | 2.0▲ | 2.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 3.0▲ |
| Skin & aesthetics | 0.0 | 1.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Kisspeptin (KP-10) | MOTS-C |
|---|---|---|
| Mechanism | KISS1 receptor agonist | Mitochondrial-derived peptide; AMPK activation / metabolic regulation |
| Route | Subcutaneous injection | Subcutaneous injection (research use) |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Kisspeptin (KP-10)?
Kisspeptin (KP-10) is a decapeptide derived from the KISS1 gene, known for its role in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis. It primarily functions by activating the KISS1 receptor (KISS1R), which stimulates the release of gonadotropin-releasing hormone (GnRH). This cascade is crucial for the regulation of reproductive hormones, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby influencing fertility and reproductive health.
Full Kisspeptin (KP-10) profile, mechanism & studies →What is MOTS-C?
MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.
Full MOTS-C profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | MOTS-C | 3.0/5 effect signal |
| Muscle | MOTS-C | 2.0/5 effect signal |
| Metabolic | MOTS-C | 4.0/5 effect signal |
| Neuro | Even | Both ~2.0/5 |
| Inflammation | MOTS-C | 3.0/5 effect signal |
| Skin | MOTS-C | 1.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Kisspeptin (KP-10) and MOTS-C?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Kisspeptin (KP-10) vs MOTS-C: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Kisspeptin (KP-10) has 25 approved studies indexed (Human clinical), and MOTS-C has 29 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Kisspeptin (KP-10) or MOTS-C better?
It depends on your goal. Kisspeptin (KP-10) is strongest for neuro; MOTS-C for metabolic. MOTS-C has more indexed studies (29). See the goal-by-goal breakdown above.
Is Kisspeptin (KP-10) or MOTS-C better for weight loss?
MOTS-C shows the stronger metabolic & appetite profile (4.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Kisspeptin (KP-10) or MOTS-C better for muscle?
MOTS-C leads on the muscle & body-composition axis (2.0/5).
Which has more research, Kisspeptin (KP-10) or MOTS-C?
Kisspeptin (KP-10) has 25 approved studies indexed (Human clinical); MOTS-C has 29 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Kisspeptin (KP-10) and MOTS-C?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Kisspeptin (KP-10) vs MOTS-C?
Kisspeptin (KP-10): no community-reported effects logged yet. MOTS-C: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Kisspeptin (KP-10) or MOTS-C FDA-approved?
Kisspeptin (KP-10) is a research-use compound and is not FDA-approved. MOTS-C is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is MOTS-C better than Kisspeptin (KP-10)?
For metabolic, MOTS-C has the edge; for neuro, Kisspeptin (KP-10) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Kisspeptin (KP-10) and MOTS-C are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.